Clinical Trials Arena May 24, 2024
Shares in the pharma company rose 40% in pre-market trading.
Verastem Oncology reported positive initial results from an ongoing Phase I/II trial investigating kinase inhibitor avutometinib for the treatment of pancreatic cancer.
The US biopharma company announced the initial interim safety and efficacy results as it gears up for a presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting on 1 June 2024.
Verastem’s trial, named RAMP 205, is a single-arm study evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel, the latter two being standard-of-care chemotherapy, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Out of the six patients receiving 2.4mg avutometinib, five achieved a confirmed overall response rate (ORR). The 83% ORR exceeds...
Today's Sponsors
Today's Sponsor